| Gene symbol | IL23A | Synonyms | IL-23, IL-23A, IL23P19, P19, SGRF | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q13.3 | dbXrefs | |
| Description | interleukin 23 subunit alpha | ||||
| Gene symbol | IL36G | Synonyms | IL-1F9, IL-1H1, IL-1RP2, IL1E, IL1F9, IL1H1, IL1RP2 | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2q14.1 | dbXrefs | |
| Description | interleukin 36 gamma | ||||
| Gene symbol | TNFSF4 | Synonyms | CD134L, CD252, GP34, OX-40L, OX4OL, TNLG2B, TXGP1 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q25.1 | dbXrefs | |
| Description | TNF superfamily member 4 | ||||
| GTO ID | GTC2011 |
| Trial ID | NCT03739931 |
| Disease | Lymphoma |
| Altered gene | TNFSF4|IL-23|IL36G |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA |
| Treatment | mRNA-2752 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade |
| Year | 2018 |
| Country | United States|Australia|Israel |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-2752-P101|2022-001597-55 |
| Vector information | |||
|
|||
| Cohort1: mRNA-2752 | |||||
|
|||||
| Cohort2: mRNA-2752_Durvalumab | |||||
|
|||||